This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adam, O. Articles by Laufs, U. Search for Related Content PubMed PubMed Citation Articles by Adam, O. Articles by Laufs, U. Related Collections Primary prevention Secondary prevention Arrhythmias, clinical electrophysiology, drugs Oxidant stress

(Circulation. 2008;118:1285-1293.)
© 2008 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors

Oliver Adam, MD; Hans-Ruprecht Neuberger, MD; Michael Böhm, MD; Ulrich Laufs, MD

From the Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin; Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.

Correspondence to Oliver Adam, MD, Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, 66424 Homburg/Saar, Germany. E-mail o.adam@freenet.de

Key Words: atrial fibrillation • statins • prevention • inflammation • oxidative stress • review

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
A trial fibrillation (AF) is the most common arrhythmia. The prevalence of AF is estimated at 0.4 to 1% of the general population, increasing with age to >8% in those over 80 years of age.^1–6 AF is also the most frequent complication after cardiac surgery, with an incidence of 30% after coronary artery bypass grafting⁷ and up to 60% after valve replacement.⁸ AF is complicated by an increased risk of stroke and increased mortality.⁹ Postoperative AF is also associated with a longer hospital stay and causes significant additional costs.^8,10–19 Anticoagulation, rate control, and rhythm control strategies are treatment options of AF. Theoretically, establishment and maintenance of sinus rhythm would be hemodynamically beneficial and should reduce symptoms, morbidity, and mortality. However, large studies could not demonstrate that rhythm control is superior to rate control.^20,21 Therefore, strategies to prevent AF (eg, in patients undergoing cardiac surgery) are needed.

Here, we review recent mechanistic and clinical evidence suggesting an additional preventive strategy for patients at risk for AF and patients after thoracic and cardiac surgery, namely, treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). We discuss recent data suggesting that in addition to cholesterol lowering, statins exert antiarrhythmic effects by improving endothelial nitric oxide (NO) availability and reducing inflammation, oxidative stress, and neurohormonal activation.

	Methods

 
A systematic literature search was conducted to identify studies evaluating pharmacological strategies to prevent AF published between 1966 and November 2007. The search technique included computerized Medline searches that used the combination of the search term "atrial fibrillation" . . . [Full Text of this Article]

This article has been cited by other articles:

				A. P. Maggioni, G. Fabbri, D. Lucci, R. Marchioli, M. G. Franzosi, R. Latini, G. L. Nicolosi, M. Porcu, F. Cosmi, S. Stefanelli, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial Eur. Heart J., October 1, 2009; 30(19): 2327 - 2336. [Abstract] [Full Text] [PDF]

				H. Ashikaga and J. E Marine Prevention of atrial fibrillation: another good reason to recommend statins to women? Heart, May 1, 2009; 95(9): 693 - 694. [Full Text] [PDF]

				E. J. Benjamin, P.-S. Chen, D. E. Bild, A. M. Mascette, C. M. Albert, A. Alonso, H. Calkins, S. J. Connolly, A. B. Curtis, D. Darbar, et al. Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop Circulation, February 3, 2009; 119(4): 606 - 618. [Abstract] [Full Text] [PDF]

				M. D. Smit and I. C. Van Gelder Is inflammation a risk factor for recurrent atrial fibrillation? Europace, February 1, 2009; 11(2): 138 - 139. [Full Text] [PDF]